Xarelto

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2017
02420082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
We describe a 64-year-old man with extensive diffuse acute lung hemorrhage, presumably as a result of anticoagulation therapy. We… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 7
Is this relevant?
2014
2014
BACKGROUND Rivaroxaban (Xarelto, Bayer HealthCare, Leverkusen, Germany) is a new oral anticoagulant drug. Anticoagulants may… (More)
Is this relevant?
2013
2013
IntroductIon In 2005, approximately 285,000 individuals underwent total hip replacement (THR) procedures, and approximately 523… (More)
  • figure 1
  • table 1
Is this relevant?
2011
2011
  • The Medical letter on drugs and therapeutics
  • 2011
The standard antithrombotic therapy for treatment of patients with acute coronary syndrome (ACS) is dual antiplatelet therapy… (More)
Is this relevant?
Review
2010
Review
2010
Several clinical candidates have now emerged as a result of an intense search for orally available, antithrombotic factor Xa… (More)
Is this relevant?
Review
2009
Review
2009
238 P&T® • May 2009 • Vol. 34 No. 5 INTRODUCTION Thromboembolic disease is associated with significant mortality and morbidity… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2009
2009
(Xarelto, Bayer Schering Pharma) is a new anticoagulant with a good oral bioavailability, acting as a potent, selective direct… (More)
Is this relevant?
2009
2009
BACKGROUND It has been estimated that major orthopaedic surgery has the highest risk of venous thromboembolism (deep vein… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Rivaroxaban (Xarelto) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of… (More)
Is this relevant?
2008
2008
BACKGROUND Prothrombin fragment 1 + 2 is excreted in urine (uF1 + 2) as a result of thrombin generation and, therefore, may be a… (More)
Is this relevant?